Naloxone

Naloxone

Form: Intravenous (IV) injection/IM/SQ

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Reference Brands: Narcan® (US); Narcan® (EU)

Category: Critical Care

Naloxone is a life-saving opioid antagonist used to reverse respiratory depression caused by opioid overdose. Available in injectable (IV, IM, SC) and intranasal forms, its strengths include 0.4 mg/mL, 1 mg/mL, and 2 mg/2 mL formats. In the US, brands like Narcan® and Kloxxado® are widely used, while EU markets rely on Prenoxad® and Nyxoid®. Naloxone is essential for hospitals, EMS, emergency kits, and addiction care facilities. Pharma B2B platforms offer bulk Naloxone procurement from GMP-certified manufacturers, ensuring reliable supply, regulatory approvals, and competitive pricing for institutions addressing the growing need for opioid reversal therapies.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (IV)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Nitroprusside

Strength: 50 mg/2 mL vial

Form: Intravenous (IV) injection

Reference Brands: Nitropress®(US), Nitroprussiat Ferrlecit®(EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.